IL233236A0 - Dosing regimen for preparations containing apolipoprotein - Google Patents

Dosing regimen for preparations containing apolipoprotein

Info

Publication number
IL233236A0
IL233236A0 IL233236A IL23323614A IL233236A0 IL 233236 A0 IL233236 A0 IL 233236A0 IL 233236 A IL233236 A IL 233236A IL 23323614 A IL23323614 A IL 23323614A IL 233236 A0 IL233236 A0 IL 233236A0
Authority
IL
Israel
Prior art keywords
dosage regime
apolipoprotein formulations
apolipoprotein
formulations
regime
Prior art date
Application number
IL233236A
Other languages
English (en)
Hebrew (he)
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905368A external-priority patent/AU2011905368A0/en
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of IL233236A0 publication Critical patent/IL233236A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL233236A 2011-12-21 2014-06-18 Dosing regimen for preparations containing apolipoprotein IL233236A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011905368A AU2011905368A0 (en) 2011-12-21 Dosing regime for apolipoprotein formulations
PCT/AU2012/001345 WO2013090978A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Publications (1)

Publication Number Publication Date
IL233236A0 true IL233236A0 (en) 2014-08-31

Family

ID=48667485

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233236A IL233236A0 (en) 2011-12-21 2014-06-18 Dosing regimen for preparations containing apolipoprotein

Country Status (16)

Country Link
US (3) US20140378376A1 (enExample)
EP (1) EP2793913B1 (enExample)
JP (2) JP6144276B2 (enExample)
KR (3) KR20140107536A (enExample)
CN (2) CN104010646A (enExample)
AU (1) AU2012310259C1 (enExample)
BR (1) BR112014014403A8 (enExample)
CA (1) CA2857968A1 (enExample)
DK (1) DK2793913T3 (enExample)
ES (1) ES2955110T3 (enExample)
IL (1) IL233236A0 (enExample)
MX (1) MX377093B (enExample)
PL (1) PL2793913T3 (enExample)
RU (1) RU2014129505A (enExample)
SG (1) SG11201402556RA (enExample)
WO (1) WO2013090978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9645037B2 (en) 2011-09-28 2017-05-09 Hunter Engineering Company Method and apparatus for wheel assembly lateral force measurement
CA2857968A1 (en) * 2011-12-21 2013-06-27 Csl Limited Dosage regime for apolipoprotein formulations
WO2018085890A1 (en) 2016-11-10 2018-05-17 Csl Limited Reconstituted high density lipoprotein treatment of myocardial infarction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
CA2460787A1 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
WO2004010939A2 (en) * 2002-07-30 2004-02-05 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
CN1870894B (zh) * 2003-10-20 2011-08-10 埃斯普里昂治疗公司 用于治疗和预防急性冠状动脉综合征的药物制剂、方法和给药方案
WO2007023476A2 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20090297577A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Local Delivery of Apolipoproteins and Their Derivatives
CA2857968A1 (en) * 2011-12-21 2013-06-27 Csl Limited Dosage regime for apolipoprotein formulations

Also Published As

Publication number Publication date
KR20200037879A (ko) 2020-04-09
BR112014014403A8 (pt) 2021-03-09
AU2012310259A1 (en) 2013-07-11
JP2015500840A (ja) 2015-01-08
KR102766038B1 (ko) 2025-02-12
MX2014006589A (es) 2014-10-17
AU2012310259C1 (en) 2016-07-14
RU2014129505A (ru) 2016-02-10
HK1199813A1 (en) 2015-07-24
JP2017128586A (ja) 2017-07-27
EP2793913A1 (en) 2014-10-29
PL2793913T3 (pl) 2023-11-06
RU2017129700A (ru) 2019-02-04
US20160175392A1 (en) 2016-06-23
US20140378376A1 (en) 2014-12-25
BR112014014403A2 (pt) 2017-06-13
US20240216467A1 (en) 2024-07-04
DK2793913T3 (da) 2023-08-21
RU2017129700A3 (enExample) 2021-02-26
EP2793913B1 (en) 2023-06-21
CN104010646A (zh) 2014-08-27
EP2793913A4 (en) 2015-06-10
NZ624558A (en) 2015-08-28
WO2013090978A1 (en) 2013-06-27
JP6144276B2 (ja) 2017-06-07
SG11201402556RA (en) 2014-10-30
KR20140107536A (ko) 2014-09-04
KR20190084334A (ko) 2019-07-16
MX377093B (es) 2025-03-07
CN113398245A (zh) 2021-09-17
AU2012310259B2 (en) 2015-07-30
CA2857968A1 (en) 2013-06-27
ES2955110T3 (es) 2023-11-28

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
GB201113662D0 (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
PL2776416T3 (pl) Związki farmaceutyczne
ZA201308208B (en) Pharmaceutical compositions
SI2672973T1 (sl) Režim dajanja nitrokaterolov
IL232305A0 (en) pharmaceutical preparations
IL228821A0 (en) Pharmacy preparation
GB201119799D0 (en) Pharmaceutical compounds
ZA201403832B (en) Pharmaceutical compounds
GB201118876D0 (en) Pharmaceutical compounds
GB201113163D0 (en) Pharmaceutical compounds
GB201118181D0 (en) Pharmaceutical compositions
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
IL233236A0 (en) Dosing regimen for preparations containing apolipoprotein
HUP1100444A2 (en) Pharmaceutical composition
HUP1100445A2 (en) Pharmaceutical composition
AU2011905368A0 (en) Dosing regime for apolipoprotein formulations
GB201111577D0 (en) Pharmaceutical formulations
GB201113730D0 (en) Solid dosage form
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201118875D0 (en) Pharmaceutical compounds
GB201105026D0 (en) Pharmaceutical compounds
GB201117359D0 (en) Pharmaceutical compounds
GB201118874D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed